



AUG 2 9 2002

**TECH CENTER 1600/2900** 

WATTED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 2023I
www.uspto.gov

APPLICATION NUMBER

FILING/RECEIPT DATE

FIRST NAMED APPLICANT

ATTORNEY DOCK T NUMBER

10/073,644

02/11/2002

Debra Hudson

MXI-211

000959 LAHIVE & COCKFIELD 28 STATE STREET

**BOSTON, MA 02109** 

Debra Hudso

CONFIRMATION NO. 6293

Date Mailed: 07/30/2002

## NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

• The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d). Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:


- For Rules Interpretation, call (703) 308-4216
- To Purchase Patentin Software, call (703) 306-2600
- For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

A copy of this notice MUST be returned with the reply.

**Customer Service Center** 

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE





AUG 2 9 2002

Page 1 of 1

**TECH CENTER 1600/2900** 

**FORMALITIES LETTER** 

United States Patent and Trademark Office

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 2023I
www.usplo.gov

APPLICATION NUMBER

FILING/RECEIPT DATE

FIRST NAMED APPLICANT

ATTORNEY DOCKET NUMBER

10/073,644

02/11/2002

Debra Hudson

MXI-211

**CONFIRMATION NO. 6293** 

000959 LAHIVE & COCKFIELD 28 STATE STREET BOSTON, MA 02109

DOCKETED COOK

Date Mailed: 07/30/2002

Fals. 83. 2003 - E.S.P. W/5 MOX.

## NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

• The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d). Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase Patentin Software, call (703) 306-2600
- For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

A copy of this notice MUST be returned with the reply.

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 1 - ATTORNEY/APPLICANT COPY

DOCKET DEPT. AUG -15 2002

ECEIVED & COCKFIELL

RETRIEVED S

1



I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the

COPY OF PAPERS ORIGINALLY FILED

Docket No.: MXI-211 (PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

AUG 2 9 2002

Application No.: 10/073644

In re Patent Application of:

Debra Hudson, et al.

Group Art Unit: 1636

TECH CENTER 1600/2900

Filed: February 11, 2002

Examiner: Not Yet Assigned

For: HUMAN MONOCLONAL ANTIBODIES TO FC

ALPHA RECEPTOR (CD89)

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Commissioner for Patents Washington, DC 20231

Dear Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, Applicants respectfully submit another copy of the Sequence Listing Diskette to replace the Sequence Listing Diskette which was filed on February 11, 2002 and subsequently damaged. No new matter has been added.

Please charge any necessary fees to our Deposit Account No. 12-0080. A duplicate copy of this paper is enclosed.

Dated: August 20, 2002

Respectfully submitted,

Jeanne M. DiGiorgio
Registration No.: 41,740
LAHIVE & COCKFIELD, LLP
28 State Street
Boston, Massachusetts 02109
(617) 227-7400
(617) 742-4214 (Fax)
Attorneys for Applicant



ide this box PTC/SB/21 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE spond to a collection of information unless it displays a valid OMB control number. Paperwork Reduction Act of 1995, no persons are re **Application Number** 10/073644 **TRANSMITTAL** Filing Date February 11, 2002 REGEIVE **FORM** First Named Inventor Debra Hudson AUG 2 9 2002 (to be used for all correspondence after initial filing) Group Art Unit 1636 Not Yet Assigned TECH CENTER 1600/2 **Examiner Name** Total Number of Pages in This Submission Attorney Docket Number MXI-211 ENCLOSURES (check all that apply) Fee Transmittal Form Assignment Papers After Allowance Communication (for an Application) to Group Fee Alitached Drawing(s) Appeal Communication to Board of Appeals and Interferences Amendment/Reply Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) Livensing-rolated Papers After Final Petitica Proprietary Information Affidavits/dಲದೆ೭.ration(s) Petition to Convert to a Provisional X Return Receipt Postcard Extension of Time Request Power of Attorney, Revocation Offier Enclosure(s) Change of Correspondence Address Express Abandonment Request Termina! Diadaimer 1. Response to Motice to Comply with Requirements for Patent Applications Containing Mucleotide Sequence and/or Amino Acid Sequence Disclosures: 2. Copy of Holice to Comply with Requirements for Patent Applications Containing information Disclosure Statement Request for Refund Machenide Sequence andre Amino Acid Sequence Disclosures, Certified Copy of Priority 1 Sequence Listing and 1 Diskette Document(s) 4. Statement personal to 37 CFR 1,821(F); Response to Missing Parts/ Incomplete Application Remarks Response to Missing Parts under 37 CFR 1.52 or 1.53 Please charge any necessary fees to our Deposit Account No. 12-0080. The undersigned requests any extensions of time necessary to respond. A duplicate of this sheet is enclosed. SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm LAHIVE & COCKFIELD, LLP Jeanne M. DiGiorgio - 41,710 Individual Name Signature enne Date August 20, 2002

I hereby cartify that this of envelope addressed to:	correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an Commissioner for Patents, Washington, DC 20231, on the date shown below.
Dated: August 20, 2002	